Clay B. Siegall, Ph.D.
President and Chief Executive Officer
Clay B. Siegall, Ph.D., co-founded Seattle Genetics in 1998 and is the company's President, Chief Executive Officer and Chairman of the Board. Under his leadership, Seattle Genetics has built a diverse pipeline of therapies to address unmet medical needs of cancer patients based on the company’s industry-leading antibody-drug conjugate (ADC) technology. Seattle Genetics' first ADC product, ADCETRIS® (brentuximab vedotin), was granted accelerated approval by the FDA in 2011 and approval with conditions by Health Canada in 2013, making it the first in a new class of ADCs. In addition, under our collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. ADCETRIS is one of more than 15 ADCs in clinical development by Seattle Genetics and its collaborators, including Genentech (Roche), Millennium: The Takeda Oncology Company and Agensys (Astellas).
Dr. Siegall has also guided Seattle Genetics’ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001.
Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He also serves on the Boards of Directors of Alder BioPharmaceuticals and Mirna Therapeutics. Dr. Siegall is an author on more than 70 publications and holds 15 patents. He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.